• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为精神药理学临床结果衡量指标的受助或受伤害可能性

Likelihood of Being Helped or Harmed as a Measure of Clinical Outcomes in Psychopharmacology.

作者信息

Andrade Chittaranjan

机构信息

Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India.

出版信息

J Clin Psychiatry. 2017 Jan;78(1):e73-e75. doi: 10.4088/JCP.16f11380.

DOI:10.4088/JCP.16f11380
PMID:28129502
Abstract

The likelihood of being helped or harmed (LHH) ratio is an indirect measure of effect size. It tells the reader how much as likely a patient is to benefit from a treatment as to suffer from an adverse outcome with that treatment; larger values for LHH indicate more favorable treatment outcomes. The numerator for LHH is usually a measure of response or remission with a treatment, and the denominator is usually a measure of all-cause discontinuation or discontinuation due to adverse events; so, there can be more than 1 LHH statistic for a study. As an example, an LHH of 5 could indicate that after removal of placebo effects a patient is 5 times as likely to respond to a treatment as to drop out of treatment because of the experience of an adverse event. This article explains the LHH with the help of a worked example, shows how the LHH can be derived from the numbers needed to treat and harm (NNT, NNH) statistics, discusses practical issues related to the concept, and considers its limitations. The LHH is little used in clinical psychopharmacology, and authors who report or review clinical trial data should consider presenting all the LHH information that is clinically relevant in addition to NNT, NNH, and other information. Because LHH statistics present the results of risk-benefit trade-off analyses, they can help clinicians and patients more easily evaluate potential treatments during decision-making processes.

摘要

获益或受损可能性(LHH)比值是效应大小的一种间接度量。它向读者表明患者从一种治疗中获益的可能性与因该治疗而出现不良结局的可能性之比;LHH值越大表明治疗结局越有利。LHH的分子通常是治疗反应或缓解的一种度量,分母通常是全因停药或因不良事件停药的一种度量;因此,一项研究可能有不止一个LHH统计量。例如,LHH为5可能表明去除安慰剂效应后,患者对治疗产生反应的可能性是因不良事件经历而退出治疗可能性的5倍。本文借助一个实例解释LHH,展示LHH如何从治疗与伤害所需数量(NNT、NNH)统计量中推导得出,讨论与该概念相关的实际问题,并考虑其局限性。LHH在临床精神药理学中很少使用,报告或综述临床试验数据的作者除了NNT、NNH和其他信息外,还应考虑呈现所有临床相关的LHH信息。由于LHH统计量呈现了风险 - 获益权衡分析的结果,它们可以帮助临床医生和患者在决策过程中更轻松地评估潜在治疗方法。

相似文献

1
Likelihood of Being Helped or Harmed as a Measure of Clinical Outcomes in Psychopharmacology.作为精神药理学临床结果衡量指标的受助或受伤害可能性
J Clin Psychiatry. 2017 Jan;78(1):e73-e75. doi: 10.4088/JCP.16f11380.
2
Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed.达力新药用于治疗慢性失眠障碍患者:需要治疗的人数、需要伤害的人数,以及帮助或伤害的可能性。
Postgrad Med. 2024 May;136(4):396-405. doi: 10.1080/00325481.2024.2359891. Epub 2024 Jun 13.
3
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?鲁拉西酮用于成人精神分裂症的急性治疗:治疗所需人数、伤害所需人数以及获益或伤害可能性分别是多少?
Clin Schizophr Relat Psychoses. 2012 Jul;6(2):76-85. doi: 10.3371/CSRP.6.2.5.
4
When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.差异何时产生差异?治疗需要人数、伤害需要人数以及可能受益或受害的解释。
Int J Clin Pract. 2013 May;67(5):407-11. doi: 10.1111/ijcp.12142.
5
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.有症状的神经源性直立性低血压患者使用屈昔多巴的需治疗人数分析。
BMC Neurol. 2016 Aug 18;16(1):143. doi: 10.1186/s12883-016-0665-5.
6
Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.普拉克索治疗帕金森病精神病:需要治疗的人数、需要伤害的人数,以及可能受益或受害的可能性。
CNS Spectr. 2018 Jun;23(3):228-238. doi: 10.1017/S1092852917000736. Epub 2017 Nov 3.
7
Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.评估依他佐辛鼻喷雾剂治疗成人治疗抵抗性抑郁症:需要治疗的人数、需要伤害的人数以及帮助或伤害的可能性。
J Affect Disord. 2020 Jun 15;271:228-238. doi: 10.1016/j.jad.2020.03.106. Epub 2020 Apr 3.
8
Lemborexant and Daridorexant for the Treatment of Insomnia: An Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.仑美曲索和达鲁氯胺治疗失眠的间接比较:使用需要治疗的人数、需要伤害的人数和帮助或伤害的可能性。
J Clin Psychiatry. 2023 Oct 2;84(6):23m14851. doi: 10.4088/JCP.23m14851.
9
Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.卢美哌隆治疗精神分裂症:需要治疗的人数、需要伤害的人数以及可能受益或受损的可能性。
J Clin Psychiatry. 2023 Mar 6;84(2):22r14631. doi: 10.4088/JCP.22r14631.
10
Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review.大型骨科手术后患者抗栓治疗的获益-风险比:系统评价。
Thromb Haemost. 2014 Feb;111(2):199-212. doi: 10.1160/TH13-08-0654. Epub 2013 Oct 24.

引用本文的文献

1
Likelihood-of-harm/help of microsurgery compared to radiosurgery in large vestibular schwannoma.大型前庭神经鞘瘤显微手术与放射手术的危害/益处比较。
J Neurooncol. 2024 Sep;169(2):299-308. doi: 10.1007/s11060-024-04732-0. Epub 2024 Jun 29.
2
Effect of M247 Administration on Pregnancy Outcomes in Women Undergoing IVF: A Controlled, Retrospective, Observational, and Open-Label Study.M247给药对接受体外受精的女性妊娠结局的影响:一项对照、回顾性、观察性开放标签研究。
Microorganisms. 2023 Nov 17;11(11):2796. doi: 10.3390/microorganisms11112796.
3
Number Needed to Quarantine and Proportion of Prevented Infectious Days by Quarantine: Evaluating the Effectiveness of COVID-19 Contact Tracing.
需要隔离的人数和通过隔离预防的感染日比例:评估 COVID-19 接触者追踪的有效性。
Public Health Rep. 2022 Nov-Dec;137(6):1178-1186. doi: 10.1177/00333549221114343. Epub 2022 Aug 20.
4
Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management.丁丙诺啡植入剂的系统效益-风险评估:一种支持风险管理的半定量方法。
BMJ Evid Based Med. 2020 Dec;25(6):199-205. doi: 10.1136/bmjebm-2019-111295. Epub 2020 Feb 24.
5
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.口服疾病修正治疗复发性多发性硬化症:无疾病活动或损害分析的可能性。
CNS Drugs. 2018 Nov;32(11):1069-1078. doi: 10.1007/s40263-018-0547-z.